In 2021, the epidemic is still ups and downs, and the “dividend” market seems to be stabilizing. From the “report card” at the end of the year, the performance of global giants is divided, most enterprises return to double-digit growth, and the “lucky ones” soar to the sky, rewriting the global market ranking pattern.
In 2021, the epidemic is still ups and downs, and the “dividend” market seems to be stabilizing. From the “report card” at the end of the year, the performance of global giants is divided, most enterprises return to double-digit growth, and the “lucky ones” soar to the sky, rewriting the global market ranking pattern.
Among the top 10, only the first and last two Medtronic and poco were not affected, and the rest were changed.
Total performance: Medtronic’s success in “defending the challenge”, Abbott’s counter attack and Roche’s focus on R & D
Medtronic had a special fiscal year range, which lagged behind other enterprises for half a year. It was greatly affected by the epidemic, but it still withstood the pressure. With a series of measures such as structural adjustment and new product relay, its performance was + 4.2% year-on-year
Abbott successfully “counter attacked” and surpassed Johnson & Johnson by leaps and bounds. It opened the gap of nearly $3 billion a year and was only one step away from the top of the list (only $100 million difference from Medtronic). Its continuous launch of popular covid-19 testing products contributed a lot.
Roche diagnosis: driven by the new crown testing business and the recovery and growth of core business, it contributed to the highest growth rate (+ 29%) in the top 10, rising 2 places to No. 6. At the same time, it is the enterprise with the highest proportion of R & D in the list.
Post time: Feb-25-2022